A multi-omics study linked a boundary-associated macrophage state to neoadjuvant resistance in gastric cancer. Using single-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence across treatment states, investigators identified an APOE+CD74+ macrophage population enriched specifically in neoadjuvant-resistant tumors. Spatial analyses placed these macrophages at tumor-stroma interfaces, where they coincided with CD8+ T cell dysfunction, increased exhaustion, and reduced cytotoxicity. Computational ligand-receptor prioritization nominated CCL3–CCR5 and HLA-DQA2–LAG3 axes as candidate mediators of the macrophage-to-lymphocyte suppression. Functionally, the team tested interventions in a murine MFC allograft model, combining adeno-associated virus-mediated depletion of Cd74 with XELOX chemotherapy. The findings position niche-targeted immune modulation as a potential resistance counter-strategy, though the work remains preclinical.